Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.3900 (1.75%) ($6.2700 - $6.5000) on Fri. May. 3, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.87% (three month average) | RSI | 48 | Latest Price | $6.3900(1.75%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.2% a day on average for past five trading days. | Weekly Trend | ADMS declines -0.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XOP(12%) OIH(11%) EWI(9%) ONLN(9%) XRT(9%) | Factors Impacting ADMS price | ADMS will decline at least -2.435% in a week (0% probabilities). BNDX(-10%) GDX(-9%) GLD(-8%) GDXJ(-7%) BWX(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.435% (StdDev 4.87%) | Hourly BBV | 0 () | Intraday Trend | 1.9% | | | |
|
Resistance Level | $6.45 | 5 Day Moving Average | $6.35(0.63%) | 10 Day Moving Average | $6.34(0.79%) | 20 Day Moving Average | $6.45(-0.93%) | To recent high | -47.4% | To recent low | 2.2% | Market Cap | $181m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |